BCMA/CD47-directed UCAR-T cells showed potent responses against primary human MM cells and MM cell lines in vitro and in vivo, and prolonged the survival of tumor-engrafted NCG mice in vivo, which provides a potential strategy for the development of a novel “off-the-shelf” cellular immunotherapies for the treatment of multiple myeloma. This evidence concerns the gene CD47 and Miyoshi myopathy.